This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-06 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Molecular analysis of DNA sequences from most families of flowering plants enabled the Angiosperm Phylogeny Group to publish in 1998 a phylogeny of flowering plants, answering many of the questions about relationships among angiosperm families and species. The theoretical possibility of a practical method for the identification of plant species and commercial varieties by DNA barcoding is the subject of active current research.
In April 2013, Hird, as coach, was accused of being personally injected with supplements in 2011 and 2012 that would be deemed performance enhancing if he were a player. Essendon players from 2011 and 2012 were also accused of ingesting performance enhancing supplements. As head coach, Hird was subsequently implicated. Following months of rumours and investigations, on 13 August 2013, Hird, along with the Essendon Football Club, senior assistant coach Mark Thompson, football manager Danny Corcoran and club doctor Bruce Reid, was charged by the AFL with bringing the game into disrepute in relation to the poor governance of the supplements program at the club in 2011 and 2012. The club was given 14 days to consider the charges and faced an AFL Commission hearing on 26 August 2013. On 27 August 2013, following much negotiation, Hird accepted charges that he had brought the game into disrepute and abandoned possible Supreme Court action against the AFL and its chief executive, Andrew Demetriou. He maintained that he did little wrong, but said he should have known more about the club's supplements program. He was banned from working at any AFL club in any capacity for twelve months commencing from 25 August 2013. Hird was allowed to attend Essendon matches as a spectator during this period. However, despite not being allowed to pay him for working as a coach during 2014, the club paid Hird $1 million in advance for 2014 in December 2013. A media report on 3 October 2013 said that Hird denied pleading guilty for a reduced charge as alleged by Demetriou.
Yosha & Bolnick & Koyle (2012) have suggested that a factor in its Anglophonic adoption and dismissal in mainland Europe relates to attitudes towards Judaism and Jewish practices. While many of these Anglophonic polities would not be considered tolerant by modern standards: the United Kingdom had Benjamin Disraeli—a Jew—as Prime Minister; Jews in the United States were prominent and generally well-respected; while in Australia "the racial issues of the time involved primarily Aborigines and Chinese immigration, and Jews were essentially below the radar". They argue that once "a substantial proportion of the male population [was] circumcised, the idea that it [was] a Jewish practice [became] no longer relevant. In Britain this was aided by the fact that circumcision was well known to be as much a practice of the nobility as a Jewish religious rite, so that the racial-religious nexus was broken." These factors were absent in continental Europe. Rates in the Anglophonic world began to sharply diverge after 1945.
The cars (outfitted with state-of-the-art fiberglass insulation and axle-driven fans for internal air circulation) traveled throughout the Southern Pacific and Union Pacific systems, where they were displayed to promote PFE's post-World War II modernization. Though both units remained in service over 15 years (#45698 was destroyed in a wreck in May 1962, while #44739 was scrapped in 1966), no additional aluminum reefers were constructed. Fruit Growers Express number 38374 was equipped with an experimental aluminum body in the Indiana Harbor, Indiana shops.
At low temperatures, the dominance of the T1.5 thermal conductivity contribution of the out-of-plane mode supersedes the T2 dependence of the linear modes. Some graphene phonon bands exhibit negative Grüneisen parameters, resulting in negative thermal expansion coefficient at low temperatures. The lowest negative Grüneisen parameters correspond to the lowest transverse acoustic ZA modes, whose frequencies increase with in-plane lattice parameter, akin to a stretched string with higher frequency vibrations.
Sources: en.wikipedia.org
== Inherited thrombocytopenia with normal MPV == ATRUS Syndrome Thrombocytopenia 2 (THC2) Congenital amegakaryocytic thrombocytopenia TAR syndrome Familial platelet disorder with predisposition to AML
== Nomenclature == Signal peptides are not to be confused with the leader peptides sometimes encoded by leader mRNA, although both are sometimes ambiguously referred to as "leader peptides." These other leader peptides are short polypeptides that do not function in protein localization, but instead may regulate transcription or translation of the main protein, and are not part of the final protein sequence. This type of leader peptide primarily refers to a form of gene regulation found in bacteria, although a similar mechanism is used to regulate eukaryotic genes, which is referred to as uORFs (upstream open reading frames).
=== Available forms === Propoxyphene was initially introduced as propoxyphene hydrochloride. Shortly before the patent on propoxyphene expired, propoxyphene napsylate form was introduced to the market. The napsylate salt (the salt of naphthalene-2-sulfonic acid) is claimed to be less prone to non-medical use, because it is almost insoluble in water, so cannot be used for injection. Napsylate also gives lower peak blood level. Because of different molar mass, a dose of 100 mg of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg of propoxyphene hydrochloride. Before the FDA-directed recall, dextropropoxyphene HCl was available in the United States as a prescription formulation combined with paracetamol (acetaminophen) in ratio from 30 mg / 600 mg to 100 mg / 650 mg (or 100 mg / 325 mg in the case of Balacet), respectively, usually named Darvocet. In Australia, dextropropoxyphene is available on prescription, both as a combined product (32.5 mg dextropropoxyphene per 325 mg paracetamol branded as Di-gesic, Capadex, or Paradex; it is also available in pure form (100 mg capsules) known as Doloxene, however its use has been restricted.
== Formation == Initial funding for the formation of Onyx came from biotechnology firm Chiron Corporation (granted a 43% stake in the new company) and venture capital investors: Avalon Ventures, Institutional Venture Partners (IVP), J. H. Whitney & Company and Kleiner Perkins. McCormick had been working on cancer treatments at Chiron before he was selected as vice president of research at the newly formed company, leading the company's research program. The acting president of the firm at its inception was Samuel D. Colella, a partner at early investor, IVP.
=== Mechanism of Action === AMPA receptors are integral to fast excitatory neurotransmission in the CNS. Each receptor is a tetramer composed of four subunits, each providing a binding site for agonists like glutamate. The ligand-binding domain is formed by the N-terminal tail and the extracellular loop between transmembrane domains three and four. The subunit composition significantly influences the receptor's functional properties, including ion permeability and gating kinetics.
Sources: en.wikipedia.org
A media blackout was imposed, white civilians evacuated further south, public assembly rights revoked, and the security forces empowered to detain suspicious persons indefinitely. Police reinforcements were sent to the border, and in the ensuing crackdown they arrested 213 Ovambos. South Africa was sufficiently alarmed at the violence to deploy a large SADF contingent as well. They were joined by Portuguese troops who moved south from across the border to assist them. By the end of March order had been largely restored and most of the remaining strikers returned to work.
negative supercoiling The supercoiling of a double-stranded DNA molecule in the direction opposite to the turn of the double helix itself (e.g. a left-handed coiling of a helix with a right-handed turn). Contrast positive supercoiling.
== Structure and bonding == Most organomercury compounds feature diamagnetic Hg(II) and adopt a linear C−Hg−X structure. Indeed, no organic derivatives of Hg2+2 are known, as Hg2+2 requires electronegative substituents for condensed-phase stability. Hg(II) derivatives are neither Lewis basic or Lewis acidic. They are stable to oxygen and water, indicating the low polarity of the Hg−C bond. The structure of "mercurocene" is instructive. When made in the 1950s, it was too sensitive for structural determination. Later analysis determined that the products have the mercury σ-bonded to just one carbon of each ring, rather than a metallocene with the metal bonded to the rings' π systems.
=== 7 July === Russian forces claimed to have taken the settlement of Chyhari (part of Pivdenne) in Donetsk Oblast. Four people were killed after their vehicle struck a Russian-planted mine in Kharkiv Oblast. Russian officials claimed that Iskander ballistic missiles destroyed two Patriot missile launchers in Odesa. The Ukrainian Air Force confirmed the attack but provided no further information. The Ukrainian military claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast. Russian officials claimed that falling debris from Ukrainian drones set fire to a warehouse in Voronezh Oblast which contained explosives. Another drone was reported shot down over Belgorod Oblast. Explosions were reported at a number of locations around occupied Melitopol, including the Melitopol Air Base, the railway station and other areas. Locals said that Russian air defence was activated during the incident.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.